BD launches diabetes pen needle with Pentapoint 5-Bevel technology

BD Micro-Fine Ultra helps to enhance patient comfort

BD Micro-Fine Ultra with Pentapoint needle tip

BD has announced the UK launch of its Micro-Fine Ultra with 5-bevel needle technology, clinically demonstrated to improve injection comfort for diabetes patients, and enhance the injection advantages of the current BD Micro-Fine+ Pen Needle.

A patient study found the five-bevel pen needles to be less painful, easier to insert and more comfortable when compared with current three-bevel pen needles. This new Pentapoint 5-bevel technology is the next in a series of innovations to come from BD Medical – Diabetes Care, resulting in a BD Premium Pen Needle product line which will be called BD Micro-Fine Ultra.

Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to give themselves insulin injections for reasons that include needle anxiety. Also, patients who reported injection-related pain or embarrassment intentionally skipped insulin injections more often. The BD Micro-Fine Ultra Pen Needle with Pentapoint technology reduces skin penetration force by 23% on average, and is clinically demonstrated to reduce the pain of injections. This may help people with diabetes adhere to an insulin injection regimen and improve outcomes with greater comfort and ease of use.

The BD Micro-Fine Ultra with Pentapoint needle tip is specially designed with five-beveled edges to create a flatter, thinner surface to penetrate the skin with significantly greater ease, for a smoother and more comfortable injection experience, compared to previous generation three bevel needles. Pentapoint technology is available in 4mm pen needles.

Matthias Borst, vice president/general manager for Europe at BD Medical’s Diabetes Care unit, said: “BD Diabetes Care has been a leader in diabetes injection devices for almost 90 years and is committed to helping improve the injection experience for the millions of people living with diabetes through ongoing patient education, the constant pursuit of innovation and improvement, and the development of high-quality products that make a difference.

“Building on the introduction of the BD Micro-Fine+ 4mm Pen Needle in 2010, we are confident that our new Pentapoint technology will provide an even-more-comfortable injection experience, helping to minimise injection resistance, fear and anxiety in people with diabetes, enabling them more easily to adopt and adhere to the therapy regimens recommended to improve their diabetes care.”

The BD Micro-Fine Ultra 4mm Pen Needle is proven to be as effective as longer needles for patients of all body types, and provides equivalent glucose control by more effectively delivering the insulin dose to subcutaneous tissue (the layer of fat below the skin), the recommended site for insulin injections, and reducing the risk of injecting into muscle. Intramuscular injection can accelerate insulin absorption and increase the risk of hypoglycemia (abnormally low blood sugar). Subcutaneous injection allows the insulin to be absorbed at an appropriate rate, resulting in better glycaemic control.

Companies